Browse studies

Find your next paid study

3,220 recruiting studies matching your filters

Connecting Through Cancer: Feasibility of a Peer Support Program for Head and Neck Patients

This clinical trial tests whether a peer support program is feasible for head and neck cancer patients. Social support at the time of diagnosis has been shown …

Malignant Head and Neck Neoplasm

Estimated

~$10 – $1,125

Actual pay is set by the research site.

OHSU Knight Cancer InstituteNCT07664241

Phase 1

A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resista…

Metastatic Castration Resistant Prostate CancermCRPCmCRPC (Metastatic Castration-resistant Prostate Cancer)+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Flare Therapeutics Inc.

Phase 2

A Biomarker-Guided Phase 2 Study of DB107-RRV (Retroviral Replicating Vector) Combined With DB107-Flucytosine Extended-Release Tablets in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HG…

High Grade GliomaAnaplastic Astrocytoma

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Ashish ShahNCT06264388

Observational

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (dif…

Prostate CancerProstate AdenocarcinomaProstate Neoplasm

Estimated

~$10 – $750

Actual pay is set by the research site.

University of ChicagoNCT05710380

Phase 1

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), phar…

Advanced Solid TumorMetastatic Solid TumorProstate Cancer+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

MOMA TherapeuticsNCT06545942

Phase 2

Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high…

Hearing LossHead and Neck Cancer

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Institute on Deafness and Other Communication Disorders (NIDCD)NCT04915183

Observational

Flyte System Transvaginal Mechanotherapy for Urinary Incontinence in Endometrial and Cervical Cancer Survivors: A Pilot Study

This clinical trial studies how well and how easy it is to use a device called Flyte in improving problems with bladder control (urinary incontinence) among en…

Cervical CarcinomaEndometrial CarcinomaOveractive Bladder+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT07662824

Phase 2

A Multi-center, Randomized, Open-label, Parallel-group, Phase 2 Study to Evaluate the Efficacy and Safety of VS-101 in Combination With Chemoradiotherapy (CRT) in Patients With Head and Neck Cancer

This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.

Head and Neck Cancer Squamous Cell Carcinoma

Estimated

~$75 – $2,800

Actual pay is set by the research site.

VSPharmTech Co.,Ltd.NCT06959082

Phase 2

Repurposing Celecoxib to Overcome Resistance to Immunotherapy in Advanced HCC (RECON Study)

This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver…

Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Emory UniversityNCT07174570

Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treat…

NSCLC, Stage IIILocally Advanced Lung Carcinoma

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Jun Zhang, MD, PhDNCT04680377

Phase 2

A Multi-Centered Evaluation of Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma (HGG): An Approach to Drug Screening That Requires Confirmation

Better treatments are needed for high-grade gliomas (HGG), and new ways of treating this disease should be tested. The investigators want to see if giving medi…

High Grade GliomasGlioblastomaAstrocytoma+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

The Cooper Health SystemNCT07439172

Observational

Patients and Families Improving Safety in Hospitals by Actively Reporting Experiences (I-SHARE)

Hospitals ineffectively examine the safety of their processes by relying on voluntary incident reporting (VIR) by clinical staff who are overworked and afraid …

Family Reported Errors and Adverse EventsHealth DisparitiesFamily Safety Reporting+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Boston Children's HospitalNCT05407129